medical Device Manufacturing Software: Plm, Qms, Mes and Erp

In a regulated plant, the software stack is part of the quality system. Auditors do not only ask what you built; they ask how you can prove it. Medical device manufacturing software exists to make design history, device history records and traceability reproducible on demand — and each system you add carries a validation burden of its own.

Most device companies start with an eQMS because it is the system an auditor asks for first, then add PLM once the BOM and change traffic outgrow spreadsheets. MES arrives when production volume makes paper travellers a bottleneck, and ERP when lot traceability and purchasing cannot be run from accounting software. Adding all four at once tends to stall: validation effort scales with the number of interfaces, not the number of licences.

Related reading: medical device design process and documentation.

Medical device manufacturers rarely buy one system. They assemble a stack: PLM owns the design history and bill of materials, QMS owns documents, CAPA and training, MES owns the electronic device history record on the floor, and ERP owns purchasing, inventory and finance. Failures come from the seams between them, not from any single tool.

A typical stack is PLM for design data and change control, an eQMS for CAPA and document control, MES for electronic device history records on the floor, ERP for lots, inventory and purchasing, and LIMS where laboratory testing is involved. Smaller manufacturers often combine PLM and QMS in a single validated platform.

Yes. Any system used for a GxP-relevant function requires computer system validation with documented IQ, OQ and PQ, plus 21 CFR Part 11 controls for audit trails and electronic signatures. Validation effort routinely costs as much as the first year of licences.

Any software that touches a quality record must be validated under computer software assurance principles. Budget 40-80% of first-year licence cost for validation on a first implementation - user requirements, risk assessment, IQ/OQ/PQ protocols, traceability matrix and a validation summary report.

Cloud vendors that supply a validation accelerator package can cut that to 20-35%, but you still own the intended-use risk assessment. Every upgrade triggers a regression assessment, so favour vendors with predictable, documented release cycles.

A small manufacturer running a combined PLM/QMS platform can operate for $25,000 to $60,000 a year. A mid-size plant running PLM, QMS, MES and ERP together typically spends $150,000 to $500,000 annually once licences, validation and integration support are counted.

The licence fee is rarely the expensive part of medical device manufacturing software. Validation is. And validation effort is not a property of the tool — it is a property of how you intend to use it. A risk-based scope, written before procurement, is the single strongest cost control available: functions that touch product quality or records get full protocols, functions that do not get a documented rationale for lighter treatment.

Two decisions reduce the number the most: keep configuration in place of customisation wherever the process can bend, and reuse the vendor's validation package rather than rewriting protocols from scratch. Customised code is validated by you, every release, forever.

A software supplier feeding a regulated process is a supplier like any other, and auditors will ask for the qualification evidence. Do it before signature, when the vendor is motivated to answer, rather than during an inspection when they are not.

Most software-related findings are data integrity findings, and they are predictable. Walk your configured system against these attributes with a real record before an inspector does.

Individually validated systems can still produce a non-compliant plant if the joins between them are manual. The recurring failure is a part revision that is current in one system and superseded in another, which surfaces as product built to an obsolete drawing.

Resist the temptation to run phases in parallel to save calendar time. Each phase changes how people work, and the validation evidence for phase two is usually built on master data created in phase one.